Terms: = Breast cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12
1511 results:
1. pDNA-tachyplesin treatment stimulates the immune system and increases the probability of apoptosis in MC4-L2 tumor cells.
Mahmoudi-Filabadi F; Doosti A
Amino Acids; 2024 May; 56(1):34. PubMed ID: 38691208
[TBL] [Abstract] [Full Text] [Related]
2. Crosstalk of disulfidptosis-related subtypes identifying a prognostic signature to improve prognosis and immunotherapy responses of clear cell renal cell carcinoma patients.
Ren L; Liu J; Lin Q; He T; Huang G; Wang W; Zhan X; He Y; Huang B; Mao X
BMC Genomics; 2024 Apr; 25(1):413. PubMed ID: 38671348
[TBL] [Abstract] [Full Text] [Related]
3. Cyclic-NDGA Effectively Inhibits Human γ-Synuclein Fibrillation, Forms Nontoxic Off-Pathway Species, and Disintegrates Preformed Mature Fibrils.
Singh SL; Bhat R
ACS Chem Neurosci; 2024 May; 15(9):1770-1786. PubMed ID: 38637513
[TBL] [Abstract] [Full Text] [Related]
4. Immune Checkpoint Inhibitor Use During Pregnancy and Outcomes in Pregnant Individuals and Newborns.
Gougis P; Hamy AS; Jochum F; Bihan K; Carbonnel M; Salem JE; Dumas E; Kabirian R; Grandal B; Barraud S; Coussy F; Hotton J; Savarino R; Marabelle A; Cadranel J; Spano JP; Laas E; Reyal F; Abbar B
JAMA Netw Open; 2024 Apr; 7(4):e245625. PubMed ID: 38630478
[TBL] [Abstract] [Full Text] [Related]
5. Multifunctional iron-apigenin nanocomplex conducting photothermal therapy and triggering augmented immune response for triple negative breast cancer.
Chen R; Jiang Z; Cheng Y; Ye J; Li S; Xu Y; Ye Z; Shi Y; Ding J; Zhao Y; Zheng H; Wu F; Lin G; Xie C; Yao Q; Kou L
Int J Pharm; 2024 Apr; 655():124016. PubMed ID: 38503397
[TBL] [Abstract] [Full Text] [Related]
6. Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II-III breast cancer.
Garber HR; Basu S; Jindal S; He Z; Chu K; Raghavendra AS; Yam C; Santiago L; Adrada BE; Sharma P; Mittendorf EA; Litton JK
Oncotarget; 2024 Mar; 15():238-247. PubMed ID: 38502947
[TBL] [Abstract] [Full Text] [Related]
7. cancer stem cells: The important role of CD markers, Signaling pathways, and MicroRNAs.
Gholamzad A; Khakpour N; Khosroshahi EM; Asadi S; Koohpar ZK; Matinahmadi A; Jebali A; Rashidi M; Hashemi M; Sadi FH; Gholamzad M
Pathol Res Pract; 2024 Apr; 256():155227. PubMed ID: 38490099
[TBL] [Abstract] [Full Text] [Related]
8. The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling.
Li T; Niu M; Zhou J; Wu K; Yi M
Cell Commun Signal; 2024 Mar; 22(1):179. PubMed ID: 38475778
[TBL] [Abstract] [Full Text] [Related]
9. Combination of STAT3 inhibitor with Herceptin reduced immune checkpoints expression and provoked anti-breast cancer immunity: An in vitro study.
Jahangiri A; Ezzeddini R; Zounemat Kermani N; Bahrami F; Salek Farrokhi A
Scand J Immunol; 2023 Sep; 98(3):e13300. PubMed ID: 38441231
[TBL] [Abstract] [Full Text] [Related]
10. Molecular and serological biomarkers to predict trastuzumab responsiveness in HER-2 positive breast cancer.
Abdullah N; Al-Mansouri L; Ali N; Hadi NR
J Med Life; 2023 Nov; 16(11):1633-1638. PubMed ID: 38406785
[TBL] [Abstract] [Full Text] [Related]
11. Exploring genetic associations of Crohn's disease and ulcerative colitis with extraintestinal cancers in European and East Asian populations.
Yu C; Xu J; Xu S; Tang L; Han Q; Zeng X; Huang Y; Yu T; Sun Z
Front Immunol; 2024; 15():1339207. PubMed ID: 38404590
[TBL] [Abstract] [Full Text] [Related]
12. Is minimal-accessed (endoscopic- or robotic-assisted) nipple-sparing mastectomy contraindicated for large breasts?
Sae-Lim C; Lai HW; Lin SL; Huang HI; Chen ST; Chen DR
Eur J Surg Oncol; 2024 Apr; 50(4):108030. PubMed ID: 38402736
[TBL] [Abstract] [Full Text] [Related]
13. Differential effect of the duration of exposure on the carcinogenicity of cadmium in MCF10A mammary epithelial cells.
Zimta AA; Cenariu D; Tigu AB; Moldovan C; Jurj A; Pirlog R; Pop C; Gurzau ES; Fischer-Fodor E; Pop L; Braicu C; Berindan-Neagoe I
Food Chem Toxicol; 2024 Apr; 186():114523. PubMed ID: 38382870
[TBL] [Abstract] [Full Text] [Related]
14. Assessment of salivary cadmium levels and breast density in the Marin Women's Study.
George MF; Paff S; Rojo J; Powell M; Benz C; Pope K; Kerlikowske K; Shepard J; Willis M; Ereman R; Prebil L
Cancer Med; 2024 Jan; 13(2):e6973. PubMed ID: 38379324
[TBL] [Abstract] [Full Text] [Related]
15. Primary breast rhabdomyosarcoma in a 17-year-old girl.
Singotia L; Haritha VS
J Cancer Res Ther; 2023 Oct; 19(7):2070-2071. PubMed ID: 38376322
[TBL] [Abstract] [Full Text] [Related]
16. Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: a systematic review and meta-analysis.
Sala I; Pagan E; Pala L; Oriecuia C; Musca M; Specchia C; De Pas T; Cortes J; Giaccone G; Postow M; Gelber RD; Bagnardi V; Conforti F
Front Immunol; 2024; 15():1340979. PubMed ID: 38348030
[TBL] [Abstract] [Full Text] [Related]
17. Toxicity Tolerance in the Carcinogenesis of Environmental Cadmium.
Cirovic A; Satarug S
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339129
[TBL] [Abstract] [Full Text] [Related]
18. Prognostic implication of novel immune-related signature in breast cancer.
Chen B; Wu H; Fang Y; Huang G; Guo C; Chen C; He L; Chen Z; Hou X; Li C; Wu J
Medicine (Baltimore); 2024 Feb; 103(6):e37065. PubMed ID: 38335435
[TBL] [Abstract] [Full Text] [Related]
19. Immunotherapy for non-small cell lung cancer.
Kagamu H
Respir Investig; 2024 Mar; 62(2):307-312. PubMed ID: 38310751
[TBL] [Abstract] [Full Text] [Related]
20. The anti-PD-L1/ctla-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial.
Li Q; Liu J; Zhang Q; Ouyang Q; Zhang Y; Liu Q; Sun T; Ye F; Zhang B; Xia S; Zhang B; Xu B
Nat Commun; 2024 Feb; 15(1):1015. PubMed ID: 38310192
[TBL] [Abstract] [Full Text] [Related]
[Next]
